Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.

ABSTRACT: There is now growing evidence that the immune contexture influences cancer progression and clinical outcome of patients with non-small cell lung cancer (NSCLC). If chemotherapy is widely used to treat patients with advanced-stage NSCLC, it remains unclear how it could modify the immune contexture and impact its prognostic value. Here, we analyzed two retrospective cohorts, respectively composed of 122 stage III-N2 NSCLC patients treated with chemotherapy before surgery and 39 stage-matched patients treated by surgery only. In patients treated with neoadjuvant chemotherapy, the histological characteristics, the expression of PD-L1 protein, and the tumor immune microenvironment (CD8⁺ T cells, DC-LAMP⁺ mature dendritic cells, and CD68⁺ macrophages) were evalua

SUBMITTER: Remark R 

PROVIDER: S-EPMC5213838 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature